For anyone interested there’s a full page article in todays Daily Mail about a woman’s experience with PMR/GCA (See above). Sarilumab (Kevzara) is mentioned as possibly being released by NICE for PMR patients next year. I’m not sure how accurate that is.
Kevzara (Sarilumab) article in todays Daily Mail ... - PMRGCAuk
Kevzara (Sarilumab) article in todays Daily Mail about woman with PMR
Already posted - twice -
healthunlocked.com/pmrgcauk...
As I explained on one of the other threads - it may be submitted to NICE for consideration next year. It is highly unlikely to be approved then. Officially it takes just under a year
cancerresearchuk.org/about-...
But the most likely decision is strict restriction as was the case with tocilizumab for GCA - in 2018 only a 52 week supply for patients with relapsing biopsy/imaging proven GCA was approved. Six years later that is still the case, despite protestation and an appeal is underway to get it extended - after a self-funded study of the relapse rate after a stopping TCZ after a year.
NICE claimed they could only approve a year as there were no long term safety studies. TCZ has been used in rheumatology since 2012 - with no restrictions on duration of use.
I bet it’ll only be for tricky cases or something that will mean it isn’t first line for all since it’ll be very expensive. Similar to GCA and Actemra.
The article is based on this US-based study from October 2023, which includes Dr Bhaskar Dasgupta as an author:
pubmed.ncbi.nlm.nih.gov/377...
Quite rightly, those not injected with sarilumab were injected with a placebo instead. The study was funded by Sanofi and Regeneron Pharmaceuticals, the makers of sarilumab (brand name Kevzara).
Thanks. As PMR pro says I don’t think it’ll be available for us to try anytime soon.